Groups
Company Size (Fulltime employees)
Partnering Objectives
Functionality
Headquartner in China
Biotech/Pharma Category
Biotech/Pharma Asset Stage
Medtech Category
Medtech Development Stage
Index
Countries
Reset

QIAGEN United States

diagnostics
Website:
www.qiagen.com
Company Size (Fulltime employees)
5000+
Partnering Objectives
Please specify your partnering goal
CDx partnership
Headquartner in China
No
Biotech/Pharma Category
Dr. Kai Zhang
PM 
Dr. Kai Zhang
PM 
Functionality
Business Development

Rancho Santa Fe Bio,Inc. United States

We are a start-up company with a Phase III ready small molecule drug for the treatment of aortic valve stenosis. We

We licensed the drug from the Mayo Clinic and the drug has been part of the NIH's NCAT's Program in which they put in $5 million for our Phase I and Phase II clinical trials and Sanofi put in another $1 million for manufacturing.

We are raising a Series A round now and we welcome interest from Chinese investors and partners.

You can reach me at 858-205-5091.

Thanks.

----Randy Berholtz
Website:
www.rsfbio.com
Company Size (Fulltime employees)
1-10
Year of foundation
2019
Partnering Objectives
Please specify your partnering goal
Investment and Chinese partner
Headquartner in China
No
Biotech/Pharma Category
Assets Information 1
Ataciguat|Small Molecule|Aortic vale stenosis|Worldwide
Biotech/Pharma Asset Stage
Mr. Randy Berholtz
Chairman and CEO 

Reinhard Oesterle United States

We are working with life sciences companies to access China, which typically includes setting up, managing and funding local entities and/or finding local partners, investors and other resources. -;Current focus on cannabis/hemp, diagnostics, digital health.
Website:
Crosswave Management
Partnering Objectives
Headquartner in China
No
Partner 
Functionality
Management

Sandhill Angels United States

We are a group of angels selecting top companies to invest.
Website:
sandhillangels.com
Year of foundation
2000
Partnering Objectives
Headquartner in China
No
Mr. Ning Sung
Investor 
Functionality
Investment

SAPA-DC United States

NGO
Website:
Www.sapadc.org
Partnering Objectives
Headquartner in China
No
Biotech/Pharma Category
Vince Deng
President 

SGTC United States

Stanford Genome Technology Center
Website:
med.stanford.edu/sgtc
Company Size (Fulltime employees)
11-50
Partnering Objectives
Please specify your partnering goal
technology development partnership
Headquartner in China
No
Your Research Tool and Service name
genomics
Dr. Weihong Xu
Director 

SiGenex Inc United States

SiGenex mission is to make clinical genetics accessible to everyone everywhere. The company is developing a bench top sample to answer targeted genetic testing solution that can be deployed anywhere in any resource setting environment.
Website:
www.Sigenex.com
Company Size (Fulltime employees)
1-10
Year of foundation
2020
Partnering Objectives
Please specify your partnering goal
Looking for partners that can help provide prototyping services, distribution and marketing.
Headquartner in China
No
Biotech/Pharma Category
Medtech Development Stage
Mr. Tan Rasab
CEO 
Functionality
Management

Simcere of America United States

Simcere Pharmaceutical Group is a leading Chinese pharmaceutical company with full capability in discovery, development, manufacturing and commercialization. Simcere is actively looking for innovative drug candidates in multiple therapeutic areas. Simcere of America is a subsidiary of Simcere Pharmaceutical Group.
Website:
http://www.simcerebic.com/
Company Size (Fulltime employees)
5000+
Year of foundation
1995
Partnering Objectives
Please specify your partnering goal
CNS, Autoimmune and Oncology Products
Headquartner in China
Yes
Biotech/Pharma Category
Biotech/Pharma Asset Stage
Dr. Bin Zhu
Senior Director 
Functionality
Business Development

Singh Biotechnology United States

We at Singh Biotechnology (SBT) are interested in meeting with you to exploring possible opportunities for partnering/in-licensing/scientific collaboration.

 

SBT is a start-up biotech company established in 2014. We discover/develop unique and proprietary therapeutic single domain antibodies (sdAbs) for the treatment of a variety of cancers, autoimmune, ophthalmological, and viral diseases by leveraging our propriety novel technology platform. Using this technology platform SBT has been able to generate therapeutic sdAbs that specifically target intracellular molecules of interest that play an important role in the pathogenesis of disease(s). Our lead therapeutic (SBT-100) is a bi-specific sdAbs that specifically targets and inhibits intracellular KRAS and signal transducer and activator of transcription 3 (STAT3) proteins.

Website:
www.singhbiotechnology.com
Company Size (Fulltime employees)
1-10
Year of foundation
2014
Partnering Objectives
Please specify your partnering goal
Raising funds for our lead asset, SBT-100, to complete toxicology studies and then go into phase 1.
Headquartner in China
No
Biotech/Pharma Category
Assets Information 1
SBT-100 is a monomeric single domain antibody (sdAb) that binds KRAS and STAT3 with nanomolar affinity, inhibits the GTPase activity of KRAS, downregulates P-ERK, inhibits the growth of eleven aggressive human cancer in vitro, and suppresses the growth of human cancers in vivo. SBT-100 is the first sdAb to penetrate the cell membrane and give a therapeutic effect in cancers. It also crosses the blood brain barrier (BBB). Through its anti-STAT3 effects, SBT-100 downregulates the expression of VEGF and PD-L1. The significant suppression of PD-L1 expression caused by SBT-100 emphasizes its immunotherapeutic potential. With our preclinical data, the US FDA has given SBT-100 Orphan Drug Designation for pancreatic cancer and osteosarcoma. In addition, we voluntarily requested a Pre-IND review of our triple negative breast cancer (TNBC) program by the FDA. The Pre-IND briefing packet received a favorable review by the FDA of the TNBC data, our SBT-100 manufacturing process, our proposed IND-enabling toxicology studies in rats and monkeys, and our proposed Phase I studies in patients. All of the patents and technology regarding SBT-100 and our other assets are internal to our company. Nothing has been licensed from an outside entity. The patents for SBT-100 and all our other assets have been approved by the U.S.A., Japan, China, South Korea, Taiwan, Canada, Australia, and every country in Europe. These patents are being processed in every other major country and region in the world.
Biotech/Pharma Asset Stage
Slides Deck
(pdf, 1.52MB)
Ashutosh Parihar
Vice President 

Sino-American Pharmaceutical Professionals Association United States

The Sino-American Pharmaceutical Professionals Association (SAPA) was established in 1993 and is headquartered in the center of the pharmaceutical corridor in New Jersey, USA.  Since its inception, SAPA rapidly became one of the most active Chinese professional associations in the US with eight chapters and more than 6,000 members.

SAPA’s members are primarily from large and mid-sized pharmaceutical and biotech companies in the US, with areas of expertise covering almost every aspect of pharmaceutical research and development as well as production.

The organization’s large membership base and their superb scientific and technical abilities has allowed SAPA to be a key source for knowledge exchange on the latest developments in the pharmaceutical, biotechnology, and generic drug industries.

Website:
sapaweb.org
Company Size (Fulltime employees)
5000+
Year of foundation
1993
Partnering Objectives
Please specify your partnering goal
Attending the conference and look for partners
Headquartner in China
No
Biotech/Pharma Category
Xiaodong Chen
President (2021-2022) 
Functionality
Other